RESUMO
Several variations on the technique for infraclavicular brachial plexus block have been described. The coracoid infraclavicular technique has become popular because of easily identified landmarks, reliable distribution of blockade, and low risk of respiratory complications such as pneumothorax. We report a case of pneumothorax in a patient after a coracoid infraclavicular brachial plexus block. Subtleties in landmark identification and measurement may affect the risk of pneumothorax.
Assuntos
Plexo Braquial , Clavícula , Bloqueio Nervoso/efeitos adversos , Pneumotórax/diagnóstico , Plexo Braquial/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Pneumotórax/etiologiaRESUMO
BACKGROUND: Treatment of postsurgical pain is a major use of analgesics, particularly after abdominal surgery. Analgesics display a number of limiting side effects, including sedation, cognitive impairment, and ileus. Although several postoperative rodent models have been developed, these models do not address these concerns. METHODS: A model is presented in the rat in which a subcostal incision is performed, penetrating into the peritoneal cavity. The behavioral effects of this surgical procedure are assessed using exploratory locomotor activity and conditioned operant responding. The effects of morphine and ketorolac were assessed in both behavioral paradigms. RESULTS: Laparotomy decreased ambulation and rearing by approximately 50% 24 h after surgery, and stereotypy (small confined movements) was affected to a lesser degree. The effects of laparotomy on conditioned operant responding were more complex. Total number of sucrose pellets earned was decreased for 2-3 days after laparotomy; however, the amount of time required was increased for up to 2 weeks. Morphine reversed the effects of surgery on ambulation and stereotypy but not rearing, and the dose-effect curve for morphine was shifted to the left by 5 mg/kg ketorolac. Ketorolac produced significant improvement in operant responding after laparotomy, and coadministration of ineffective doses of morphine and ketorolac produced a positive response. CONCLUSION: The current model is consistent with behavioral aspects of postoperative pain seen clinically. The effects of morphine and ketorolac alone and in combination were consistent with the reported analgesic efficacy and occurrence of side effects found with these agents clinically.
Assuntos
Condicionamento Operante/fisiologia , Comportamento Exploratório/fisiologia , Laparotomia/psicologia , Dor Pós-Operatória/psicologia , Analgésicos Opioides/farmacologia , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Cetorolaco/uso terapêutico , Masculino , Morfina/farmacologia , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Ratos , Ratos Endogâmicos F344 , Comportamento Estereotipado/efeitos dos fármacos , Sacarose/farmacologiaRESUMO
OBJECTIVE: This study assessed conversion factors utilized by physicians to transfer postoperative patients from intravenous opioids to oral controlled-release (CR) oxycodone and the subsequent analgesic effectiveness. DESIGN: This was a multicenter, open-label, usual-use study of 189 hospitalized postoperative patients receiving opioid (usually morphine) intravenous patient-controlled analgesia (IV PCA) for at least 12 to 24 hours post-procedure. Patients who were tolerant of oral medications and without signs of paralytic ileus were converted to oral CR oxycodone, given every 12 hours for up to 7 days. RESULTS: The mean (+/-SE) conversion factor used to convert IV PCA morphine to CR oxycodone was 1.2 +/- 0.1 (N=159). The initial CR oxycodone doses, based on individual conversion factors from IV PCA morphine, produced significant reductions in pain intensity (scores Assuntos
Analgésicos Opioides/administração & dosagem
, Oxicodona/administração & dosagem
, Dor Pós-Operatória/tratamento farmacológico
, Administração Oral
, Adulto
, Idoso
, Preparações de Ação Retardada
, Feminino
, Humanos
, Injeções Intravenosas
, Masculino
, Pessoa de Meia-Idade
RESUMO
IMPLICATIONS: This case report describes a patient who demonstrated generalized seizure activity after an injection of 30 mL of levobupivacaine 0.5% for interscalene brachial plexus block. No evidence of cardiovascular toxicity was noted.
Assuntos
Anestésicos Locais/efeitos adversos , Plexo Braquial , Bupivacaína/efeitos adversos , Bloqueio Nervoso/efeitos adversos , Convulsões/induzido quimicamente , Adulto , Feminino , Humanos , Hipnóticos e Sedativos/uso terapêutico , Midazolam/uso terapêutico , Procedimentos Ortopédicos , Convulsões/tratamento farmacológico , Ombro/cirurgiaAssuntos
Anticoagulantes/efeitos adversos , Hematoma/etiologia , Hematoma/patologia , Plexo Lombossacral , Bloqueio Nervoso/efeitos adversos , Espaço Retroperitoneal/patologia , Idoso , Idoso de 80 Anos ou mais , Ligamento Cruzado Anterior/cirurgia , Lesões do Ligamento Cruzado Anterior , Anticoagulantes/uso terapêutico , Artroplastia do Joelho , Artroscopia , Feminino , Humanos , Joelho/cirurgia , Imageamento por Ressonância Magnética , Masculino , Tempo de Tromboplastina Parcial , Trombose/prevenção & controleRESUMO
UNLABELLED: We compared the pharmacokinetics and clinical characteristics of 0.5% levobupivacaine for axillary block in patients with normal renal function versus patients with end-stage renal disease (ESRD). Twenty patients with normal renal function and eight patients with ESRD received an axillary block with 50-60 mL of 0.5% levobupivacaine. Patients were evaluated for onset and duration of sensory/motor block. Eleven patients with normal renal function and eight patients with ESRD underwent pharmacokinetic analysis. No differences between groups were found in the onset, duration, or quality of block. The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively. No significant differences in noncompartmental pharmacokinetic variables (median) were found between normal and ESRD patients with an AUC(0-t) (microg. h(-1). mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively. This study demonstrates the clinical efficacy and equivalence of the pharmacokinetic characteristics of 0.5% levobupivacaine for axillary brachial plexus block in patients with ESRD and normal renal function. IMPLICATIONS: This study demonstrates the clinical efficacy and equivalence of the pharmacokinetic characteristics of 0.5% levobupivacaine for axillary brachial plexus block in patients with renal disease and normal renal function.